- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03850769
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
March 8, 2020 updated by: Peking Union Medical College Hospital
Prospective Phase II Single-arm Study of Neoadjuvant Nab-Paclitaxel and S-1 in Patients With Borderline Resectable Pancreatic Cancer
This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer.
A total of 60 subjects who meet the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1, for a maximum of 4 cycles prior to pancreatectomy.
The primary endpoint is R0 resection rate, the secondary endpoints include overall survival and response rate.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- YueJuan Cheng
- Phone Number: 861069158315
- Email: cnchengyuejuan@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients have good compliance, can understand the research process of this study, and sign a written informed consent
- Patients with pathologically confirmed pancreatic adenocarcinoma.
- Patients who have not received prior chemotherapy, radiotherapy or other systematic treatment for pancreatic cancer;
- Patients with borderline resectable pancreatic cancer ( NCCN Version 1,2019 criteria).
- ECOG PS 0-1;
- Tumor size is measurable according to RECIST1.1 criteria
- Expected survival over 3 months;
- Bone marrow function: neutrophils≥1.5x109/L, platelets ≥100x109/L, hemoglobin≥ 90g/L;
- Liver and kidney function: serum creatinine≤1.5ULT; AST and ALT≤ 2.5 ULT; total bilirubin ≤ 1.5 ULT;
- No contraindications to the use of S-1 and nab-paclitaxel.
Exclusion Criteria:
- ≥ Grade 2 existing peripheral neuropathy;
- Any other malignancy within 5 years prior to enrollment, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, bladder, or nonmelanomatous skin cancer.
- Active, uncontrolled infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate treatment.
Severe, active co-morbidity, defined as follows:
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months Transmural myocardial infarction within the 6 months of study registration Uncontrolled hypertension, diabetes or arrhythmia. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization.
- Not able to take medicine orally.
- Pregnancy or lactation, and women of childbearing age who refused to take appropriate contraceptive measures during the course of this study;
- Participation in other clinical trial within 30 days before the first dose of the drug;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: nab-paclitaxel and S-1
neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 4 cycles.
|
Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area < 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 < 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0 resection rate
Time Frame: 3 years
|
proportion of patients who achieved R0 resection
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2019
Primary Completion (ANTICIPATED)
March 1, 2022
Study Completion (ANTICIPATED)
April 1, 2022
Study Registration Dates
First Submitted
February 20, 2019
First Submitted That Met QC Criteria
February 20, 2019
First Posted (ACTUAL)
February 22, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 10, 2020
Last Update Submitted That Met QC Criteria
March 8, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- HS-1752
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Resectable Pancreatic Cancer
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Kimberly Perez, MDNovartisTerminatedPancreatic Cancer | Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Fudan UniversityWest China Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Zhejiang... and other collaboratorsRecruitingBorderline Resectable Pancreatic CancerChina
-
Universita di VeronaSuspendedBorderline Resectable Pancreatic CancerItaly
-
Peking Union Medical College HospitalNot yet recruitingBorderline Resectable Pancreatic Cancer
-
Galera Therapeutics, Inc.TerminatedUnresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRTUnited States, France, United Kingdom, Canada
-
Cancer Institute and Hospital, Chinese Academy...Jiangsu HengRui Medicine Co., Ltd.RecruitingBorderline Resectable Pancreatic CancerChina
-
University of Alabama at BirminghamNot yet recruitingBorderline-resectable Pancreatic CancerUnited States
-
Nagoya UniversityActive, not recruitingBorderline Resectable Pancreatic Cancer
Clinical Trials on nab-paclitaxel and S-1
-
Yang Jianjun, PhDRecruiting
-
Peking University Cancer Hospital & InstituteRecruitingGastric AdenocarcinomaChina
-
Chang Gung Memorial HospitalRecruitingMetastatic Pancreatic AdenocarcinomaTaiwan
-
Zhejiang Cancer HospitalRecruitingLocally Advanced Gastric CancerChina
-
Chinese PLA General HospitalRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal AdenocarcinomaChina
-
Zhongshan Hospital Xiamen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruiting
-
AIPING ZHOUCompleted
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Peking Union Medical College HospitalUnknownLocally Advanced Pancreatic CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingLocally Advanced Pancreatic CancerChina